{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:50:09Z","timestamp":1791111009848,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T00:00:00Z","timestamp":1158019200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Previous epidemiological studies have inconsistently shown a modestly increased breast cancer risk associated with hormone replacement therapy (HRT). Limited information is available about different formulations \u2013 particularly concerning different progestins.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A case-control study was performed within Germany in collaboration with regional cancer registries and tumor centers. Up to 5 controls were matched breast cancer cases. Conditional logistic regression analysis was applied to estimate crude and adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Stratified analyses were performed to compare the risk of different estrogens, progestins, and combinations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 3593 cases of breast cancer were identified and compared with 9098 controls. The adjusted overall risk estimate for breast cancer (BC) associated with current or past use of HRT was 1.2 (1.1\u20131.3), and almost identical for lag times from 6 months to 6 years prior to diagnosis. No significant trend of increasing BC risk was found with increasing duration of HRT use, or time since first or last use in aggregate. Many established BC risk factors significantly modified the effect of HRT on BC risk, particularly first-degree family history of BC, higher age, lower education, higher body mass index (BMI), and never having used oral contraceptives (OCs) during lifetime.<\/jats:p>\n            <jats:p>Whereas the overall risk estimates were stable, the numbers in many of the sub-analyses of HRT formulation groups (estrogens, progestins, and combinations) were too small for strong conclusions. Nevertheless, the BC risk seems not to vary much across HRT formulation subgroups. In particular, no substantial difference in BC risk was observed between HRT containing conjugated equine estrogens (CEE) or medroxyprogesterone acetate (MPA) and other formulations more common in Europe.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The BC risk of HRT use is rather small. Low risk estimates for BC and a high potential for residual confounding and bias in this observational study do not permit causal conclusions. Apparently, there is not much variation of the BC risk across HRT formulations (estrogens, progestins). However, the small numbers and the overlapping nature of some of the subgroups suggest cautious interpretation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6874-6-13","type":"journal-article","created":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T18:21:13Z","timestamp":1158085273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Breast cancer risk associated with different HRT formulations: a register-based case-control study"],"prefix":"10.1186","volume":"6","author":[{"given":"Juergen C","family":"Dinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar AJ","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"M\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Minh","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Assmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,9,12]]},"reference":[{"key":"93_CR1","first-page":"71","volume":"60","author":"MW Beckmann","year":"2000","unstructured":"Beckmann MW, Jap D, Huschel B, Dall P, Lux MP, Hanstein B, Bender HG: Wirkmechanismen ovarieller Steroidhormone und Anti\u00f6strogene in der Karzinogenese der Mamma und des Endometrium. Geburth Frauenh. 2000, 60: 71-76.","journal-title":"Geburth Frauenh"},{"key":"93_CR2","volume-title":"Oral Contraception and health. An interim report from the oral contraceptive study of the RCGP","author":"Royal College of General Practitioners","year":"1974","unstructured":"Royal College of General Practitioners: Oral Contraception and health. An interim report from the oral contraceptive study of the RCGP. 1974, (Abstract)"},{"key":"93_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","unstructured":"Writing Group for the Women's Health Initiative Investigators: Risks and benefit of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002, 288: 321-333.","journal-title":"JAMA"},{"key":"93_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","volume":"362","author":"Million Women Study Collaborators","year":"2003","unstructured":"Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in Million Women Study. Lancet. 2003, 362: 419-27.","journal-title":"Lancet"},{"key":"93_CR5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJM198011203032102","volume":"303","author":"NS Weiss","year":"1980","unstructured":"Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Eng J Med. 1980, 303: 1195-98.","journal-title":"N Eng J Med"},{"key":"93_CR6","first-page":"579","volume":"76","author":"HK Genant","year":"1990","unstructured":"Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M: Effects of estrogene sulfate on postmenopausal bon loss. Ostet Gynecol. 1990, 76: 579-84.","journal-title":"Ostet Gynecol"},{"key":"93_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF00146889","volume":"3","author":"VM Gerhardsson de","year":"1992","unstructured":"Gerhardsson de VM, London S: Reproductive factors, exogenous female hormones, and coloractal cancer by subsite. Cancer Causes Control. 1992, 3: 355-60.","journal-title":"Cancer Causes Control"},{"key":"93_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0091-7435(91)90006-P","volume":"20","author":"M Stampfer","year":"1991","unstructured":"Stampfer M, Colditz G: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991, 20: 47-63.","journal-title":"Prev Med"},{"key":"93_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7326\/0003-4819-117-12-1016","volume":"117","author":"D Grady","year":"1992","unstructured":"Grady D, Rueben SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992, 117: 1016-37.","journal-title":"Ann Intern Med"},{"key":"93_CR10","first-page":"32","volume":"10","author":"E Windler","year":"2002","unstructured":"Windler E: Hormoneresatztherapie und kardiovaskul\u00e4re Pr\u00e4vention \u2013 Chance oder Risiko. J Menopause. 2002, 10: 32-40.","journal-title":"J Menopause"},{"key":"93_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/aje\/kwi164","volume":"162","author":"RL Prentice","year":"2005","unstructured":"Prentice RL, Langer R, Stephanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, from the Women's Health Initiative Investigators: Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative Clinical Trial. Am J Epidemiol. 2005, 162: 1-11.","journal-title":"Am J Epidemiol"},{"key":"93_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/humupd\/dmh025","volume":"10","author":"ESHRE Capri Workshop Group","year":"2004","unstructured":"ESHRE Capri Workshop Group: Hormones and breast cancer. Human Reproduction update. 2004, 10: 281-93.","journal-title":"Human Reproduction update"},{"key":"93_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","volume":"350","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1997","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997, 350: 1047-59.","journal-title":"Lancet"},{"key":"93_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1055\/s-2002-32421","volume":"62","author":"LAJ Heinemann","year":"2002","unstructured":"Heinemann LAJ, Lewis MA, K\u00fchl-Habich D, Braendle W, Garbe E, M\u00f6hner S: Lifetime history of oral contraceptive use and development of cancer of the uterus and ovary. Geburth Frauenheilk. 2002, 62: 566-573.","journal-title":"Geburth Frauenheilk"},{"key":"93_CR15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1055\/s-2002-33715","volume":"62","author":"LAJ Heinemann","year":"2002","unstructured":"Heinemann LAJ, Lewis MA, K\u00fchl-Habich D, Braendle W, M\u00f6hner S: The risk of breast tumors and lifetime history of oral contraceptive use. Geburth Frauenheilk. 2002, 62: 750-757.","journal-title":"Geburth Frauenheilk"},{"key":"93_CR16","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1055\/s-2003-42732","volume":"63","author":"LAJ Heinemann","year":"2003","unstructured":"Heinemann LAJ, Lewis MA, K\u00fchl-Habich D, Braendle W, M\u00f6hner S: Use of oral contraceptives and risk of cancer of the uterus or ovary. Two case-control studies Geburth Frauenheilk. 2003, 63: 1018-26.","journal-title":"Two case-control studies Geburth Frauenheilk"},{"key":"93_CR17","volume-title":"Life and Medical Science Online","author":"LAJ Heinemann","year":"2001","unstructured":"Heinemann LAJ, Assmann A, Lewis MA: How representative can be a cohort of volunteers for the general population? The German Cohort Study on Women' Health. Life and Medical Science Online. 2001, 2: DOI:10.1072\/LO203322 (11 pages), [http:\/\/www.lamso.com]"},{"key":"93_CR18","doi-asserted-by":"publisher","first-page":"T127","DOI":"10.1016\/0010-7824(86)90079-X","volume":"33","author":"A Coulter","year":"1986","unstructured":"Coulter A, Vessey M, McPherson K: The ability of women to recall their oral contraceptive histories. Contraception. 1986, 33: T127-137.","journal-title":"Contraception"},{"key":"93_CR19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/oxfordjournals.aje.a116907","volume":"138","author":"P Nischan","year":"1993","unstructured":"Nischan P, Ebeling K, Thomas DB, Hirsch U: Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol. 1993, 138: 697-703.","journal-title":"Am J Epidemiol"},{"key":"93_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0010-7824(97)00172-8","volume":"56","author":"DJ Hunter","year":"1997","unstructured":"Hunter DJ, Manson JE, Colditz GA, Chason-Taber L, Troy L, Stampfer MJ, Speizer FE, Willet WC: Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception. 1997, 56: 373-378.","journal-title":"Contraception"},{"key":"93_CR21","unstructured":"American Institute for Cancer Research: Food, nutrition and the prevention of Cancer: a global perspective. Breast. World Cancer Research Fund and American Institute of Cancer Research, Washington (USA) DC, 252-287. 20009 ISBN: 1 899533 05 2"},{"key":"93_CR22","first-page":"217","volume":"45","author":"LAJ Heinemann","year":"2004","unstructured":"Heinemann LAJ: WHI Studie und Million Women Study aus epidemiologischer Sicht. Frauenarzt. 2004, 45: 217-22.","journal-title":"Frauenarzt"},{"key":"93_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/cmt.6.4.302.313","volume":"6","author":"S Shapiro","year":"2003","unstructured":"Shapiro S: Risk of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric. 2003, 6: 302-310.","journal-title":"Climacteric"},{"issue":"suppl","key":"93_CR24","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/0378-5122(96)01010-9","volume":"23","author":"I Persson","year":"1996","unstructured":"Persson I: Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas. 1996, 23 (suppl): S37-S45.","journal-title":"Maturitas"},{"key":"93_CR25","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/S0378-5122(99)00065-1","volume":"33","author":"HPG Schneider","year":"1999","unstructured":"Schneider HPG: HRT and cancer risk: separating fact from fiction. Maturitas. 1999, 33: S65-S72.","journal-title":"Maturitas"},{"key":"93_CR26","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"The Women's Health Initiative Randomized controlled trial","year":"2004","unstructured":"The Women's Health Initiative Randomized controlled trial: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004, 291: 1701-12.","journal-title":"JAMA"},{"key":"93_CR27","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1001\/jama.289.24.3254","volume":"289","author":"CI Li","year":"2003","unstructured":"Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR: Relationship between long duration and different regimes of hormonal therapy and risk of breast cancer. JAMA. 2003, 289: 3254-63.","journal-title":"JAMA"},{"key":"93_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1023\/A:1025635720208","volume":"14","author":"H Jernstrom","year":"2003","unstructured":"Jernstrom H, Bendahl PQ, Lidfeldt J, Nerbrand C, Agardh CD, Samsioe G: A prospective study of different types of hormone replacement therapy use und the rsik fo subsequent breast cancer. The women's health in the Lund area (WHILA) study (Sweden). Cancer Cause Control. 2003, 14: 673-80.","journal-title":"Cancer Cause Control"},{"key":"93_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/BF00052181","volume":"6","author":"AG Schuurman","year":"1995","unstructured":"Schuurman AG, van den Brandt PA, Goldbohm RA: Exoegnous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands cohort study. Cancer Causes Control. 1995, 6: 416-24.","journal-title":"Cancer Causes Control"},{"issue":"11","key":"93_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/jech.54.11.851","volume":"54","author":"RA Wiseman","year":"2000","unstructured":"Wiseman RA: Breast cancer hypothesis: a single cause for the majority of cases. J Epidemiol Community Health. 2000, 54 (11): 851-8.","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"93_CR31","first-page":"3","volume":"4","author":"B Friedenson","year":"2002","unstructured":"Friedenson B, Friedenson H: Genetic testing for breast and ovarian cancer for women with a family history of breast cancer: weighing conflicting evidence about oral contraceptives. MedGenMed. 2002, 4 (3): 3.","journal-title":"MedGenMed"},{"issue":"11","key":"93_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.7326\/0003-4819-127-11-199712010-00004","volume":"127","author":"TA Sellers","year":"1997","unstructured":"Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, Folsom AR: The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997, 127 (11): 973-80. Comment in: ACP J Club. 1998 May-Jun;128(3):74","journal-title":"Ann Intern Med"},{"issue":"14","key":"93_CR33","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1001\/jama.284.14.1791","volume":"284","author":"DM Grabrick","year":"2000","unstructured":"Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, Olson JE, Couch FJ, Anderson KE, Pankratz VS, Sellers TA: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000, 284 (14): 1837-8.","journal-title":"JAMA"},{"key":"93_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ijc.20710","volume":"114","author":"A Fournier","year":"2004","unstructured":"Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2004, 114: 448-54.","journal-title":"Int J Cancer"},{"key":"93_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/jnci\/92.4.328","volume":"92","author":"RK Ross","year":"2000","unstructured":"Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk. J Natl Cancer Inst. 2000, 92: 328-32.","journal-title":"J Natl Cancer Inst"},{"key":"93_CR36","first-page":"339","volume":"81","author":"C Magnusson","year":"1999","unstructured":"Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HQ, Persson I: Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Ant J Cancer. 1999, 81: 339-44.","journal-title":"Ant J Cancer"},{"key":"93_CR37","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/cncr.11205","volume":"97","author":"HK Olsson","year":"2003","unstructured":"Olsson HK, Ingvar C, Bladstro A: Hormone replacement therapy containing progestins and given continuously increases breast cancinoma risk in Sweden. Cancer. 2003, 97: 1387-92.","journal-title":"Cancer"},{"key":"93_CR38","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ijc.20016","volume":"109","author":"C Stahlberg","year":"2004","unstructured":"Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottensen B: Increased risk of breast cancer following different regimes of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004, 109: 721-27.","journal-title":"Int J Cancer"},{"key":"93_CR39","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/humrep\/dei043","volume":"20","author":"M Dietel","year":"2005","unstructured":"Dietel M, Lewis MA, Shapiro S: Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini review. Human Reproduction. 2005, 20: 2052-60.","journal-title":"Human Reproduction"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-6-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6874-6-13\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-6-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-6-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:27:51Z","timestamp":1630448871000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/1472-6874-6-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1186\/1472-6874-6-13","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,12]]},"assertion":[{"value":"7 April 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"13"}}